TALLC is a new pre-clinical stage pharmaceutical company developing our proprietary CB2R agonist TA-A001, and pipeline candidates, as novel mechanism anti-inflammatories and analgesics.
TALLC will focus first on meeting the demand for non-opioid, non-NSAID intravenous analgesics to manage postoperative pain. TA-A001's high potency, immediate onset, long duration of action and demonstrated synergies make it an ideal candi...
TALLC is a new pre-clinical stage pharmaceutical company developing our proprietary CB2R agonist TA-A001, and pipeline candidates, as novel mechanism anti-inflammatories and analgesics.
TALLC will focus first on meeting the demand for non-opioid, non-NSAID intravenous analgesics to manage postoperative pain. TA-A001's high potency, immediate onset, long duration of action and demonstrated synergies make it an ideal candidate for the elective ambulatory surgery market without the fear of dependence or addiction.
In parallel TALLC intends to demonstrate the value of TA-A001 as a treatment for acute and chronic eye pain.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.